CASPASE-14 POLYPEPTIDES
    51.
    发明公开
    CASPASE-14 POLYPEPTIDES 审中-公开
    胱天蛋白酶14多肽

    公开(公告)号:EP1036086A1

    公开(公告)日:2000-09-20

    申请号:EP98950774.4

    申请日:1998-09-30

    CPC分类号: C12N9/6475 C07K14/4747

    摘要: The present invention relates to a novel Caspase-14 protein (also called ERICE) which is a novel effector of apoptosis. In particular, isolated nucleic acid molecules are provided encoding the human Caspase-14 protein. Caspase-14 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Caspase-14 activity. Also provided are therapeutic methods for treating diseases and disorders associated with apoptosis.

    HUMAN ENDOKINE ALPHA
    58.
    发明公开
    HUMAN ENDOKINE ALPHA 失效
    人类Endokine ALPHA

    公开(公告)号:EP0961831A1

    公开(公告)日:1999-12-08

    申请号:EP96928886.0

    申请日:1996-08-16

    摘要: The present invention concerns a novel member of the tumor necrosis factor (TNF) family of cytokines. In particular, isolated nucleic acid molecules are provided encoding the endokine alpha protein. Endokine alpha polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic and therapeutic methods concerning TNF family-related disorders.

    摘要翻译: 本发明涉及肿瘤坏死因子(TNF)家族细胞因子的新成员。 具体而言,提供了编码内因子α蛋白的分离的核酸分子。 还提供了内因子α多肽,如载体,宿主细胞和用于生产它们的重组方法。 还提供了关于TNF家族相关疾病的诊断和治疗方法。

    CD44-LIKE PROTEIN
    60.
    发明公开
    CD44-LIKE PROTEIN 失效
    CD44样蛋白

    公开(公告)号:EP0960198A1

    公开(公告)日:1999-12-01

    申请号:EP96927373.0

    申请日:1996-08-09

    IPC分类号: C07K14 C12N1 C12N15 A61K38

    摘要: The present invention concerns a novel CD44-like protein receptor. In particular, isolated nucleic acid molecules are provided encoding the CD44-like protein. CD44-like polypeptides are also provided, as are screening methods for identifying agonists and antagonists capable of enhancing or inhibiting CD44-like protein-mediated signaling. The invention further concerns therapeutic methods for treating diseases associated with processes mediated by CD44-like protein signaling.